What NeuExcell Therapeutics does

NeuExcell Therapeutics is a clinical-stage gene therapy company developing first-in-class treatments for neurodegenerative diseases using its proprietary ATN (Astrocytes to Neurons) platform. Founded in 2016 at Penn State University, the company's core technology uses AAV vectors to deliver neural transcription factors, notably NeuroD1, that convert endogenous glial cells into functional neurons at sites of injury or disease in the brain. The platform is grounded in a decade of preclinical research by founder Gong Chen, with peer-reviewed publications in Cell Stem Cell, Nature Communications, Neuron, and Molecular Therapy. The company has three first-in-class clinical programs in malignant glioma (NXL-004), Alzheimer's disease (NXL-001), and stroke, with additional preclinical programs targeting Parkinson's disease, Huntington's disease, ALS, traumatic brain injury, spinal cord injury, and ocular diseases.

The lead clinical asset NXL-004 received FDA Orphan Drug Designation in December 2023, and Phase I results in 11 recurrent glioma patients demonstrated median survival exceeding 12 months with tumor regression in some cases. NXL-001 achieved world-first patient dosing in June 2025 in a patient with a 10-year Alzheimer's disease history, with no drug-related serious adverse events at one-month follow-up. A 2021 strategic research collaboration with Spark Therapeutics (Roche Group) extends the platform into Huntington's disease and other neurological disorders. Clinical development is executed primarily through investigator-initiated trials at leading Chinese academic medical centers, including First Affiliated Hospital of USTC.

NeuExcell operates a pre-revenue business model typical of clinical-stage gene therapy developers, with future revenue dependent on regulatory approval and commercialization of gene therapy products rather than current sales or licensing income. The company has raised over $25 million across two funding rounds (Series Pre-A in August 2021 and Series Pre-A+ in May 2023) from Chinese venture capital investors led by Co-Win Ventures. Operations span Philadelphia (US headquarters), Shanghai (regional HQ), and Suzhou (China operations), and the leadership team is anchored by Co-founder and Chief Scientific Advisor Gong Chen, Chairman Xudong Yin, and a recently expanded executive bench including a Co-CEO, CBSO, CFO/COO, and VP Research.

Name

NeuExcell Therapeutics

Legal name

NeuExcell Therapeutics Inc

Website

https://neuexcell.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

NeuExcell Therapeutics is a clinical-stage gene therapy company developing first-in-class AAV-based treatments that convert astrocytes into functional neurons in situ, targeting neurodegenerative diseases including glioblastoma, Alzheimer's, and stroke through clinical trials in the US and China.

Ownership category

akta.pro rank

Product category

Gene Therapy

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

AAV Vector Gene Therapy Developers (HLAAACAA)

akta.pro secondary industries

Neurology/CNS Gene Therapies (HLAAACAH), Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches) (HLAAACAF), Neural & Spinal Cord Regeneration (HLAAAGAI)

Keywords

• Gene therapy development
• Neurodegenerative disease treatment
• AAV gene therapy
• In situ neuroregeneration
• Neuroregenerative biotechnology

Headquarters

HQ city

King Of Prussia

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Gene Therapy Development and Commercialization: Pre-revenue clinical-stage biotech company developing proprietary gene therapies for neurodegenerative diseases. Revenue will be generated through product sales upon regulatory approval and commercialization.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

NeuExcell Therapeutics develops AAV-based gene therapies that convert endogenous astrocytes into functional neurons within the brain using its proprietary ATN (Astrocytes To Neurons) platform. The company is advancing multiple clinical-stage gene therapy candidates, including NXL-001 for Alzheimer's disease and NXL-004 for malignant glioma, targeting neurodegenerative diseases and central nervous system injuries through in situ neuroregeneration rather than symptomatic treatment.

Product overview

NeuExcell Therapeutics is a clinical-stage gene therapy company developing first-in-class treatments for neurodegenerative diseases using its proprietary ATN ASTROCYTES TO NEURONS™ platform. The platform converts endogenous glial cells (astrocytes) into functional neurons in situ using AAV-delivered neural transcription factors. The company's clinical pipeline includes NXL-004 for malignant glioma and NXL-001 for Alzheimer's disease, with three pioneering clinical trials in glioma, Alzheimer's disease, and stroke. The technology has potential applications across stroke, Parkinson's disease, Huntington's disease, ALS, traumatic brain injury, spinal cord injury, and ocular diseases.

Differentiator

Problem solved

Functional benefit

Products and services

• NXL-001 Proprietary AAV-based gene therapy that delivers the NeuroD1 neural transcription factor to reprogram astrocytes into functional neurons within the brain. Targeted for Alzheimer's disease treatment with the goal of restoring lost neuronal function and addressing the fundamental pathology of irreversible neuron loss underlying cognitive decline.
• NXL-004 AAV-based gene therapy for recurrent malignant glioma utilizing in situ conversion therapy that reprograms tumor cells into non-dividing neurons or induces cell apoptosis. Granted FDA Orphan Drug Designation in December 2023, providing incentives for rare disease drug development including seven-year market exclusivity upon approval.
• NXL-001 First Patient Dosing - Alzheimer's Disease First patient dosed milestone for NXL-001 gene therapy in a patient with ten years of Alzheimer's disease history. Assessment at one-month follow-up showed the patient well recovered with no drug-related serious adverse events, validating the safety profile of in situ neuroregenerative gene therapy in severe AD.

Quantifiable outcome

• Median survival exceeding 12 months observed in Phase I study with NXL-004 for recurrent malignant glioma
• +3 more outcomes

Named customers2 records

Segments6 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Spark Therapeutics (Roche Group)coreStrategic or Co-development Partner · 1 January 2021Strategic research collaboration entered in 2021 to advance gene therapies for neurological disorders including Huntington's disease using technology derived from the ATN platform. Spark Therapeutics is a member of the Roche Group.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Spark Therapeutics (Roche): Spark Therapeutics, a member of the Roche Group, is a leading AAV gene therapy company with active programs in neurological disorders. NeuExcell entered a strategic research collaboration with Spark in 2021 for Huntington's disease gene therapies using the ATN platform, making Spark both a strategic partner and the most directly comparable peer in AAV-based neurological gene therapy development.
• Voyager Therapeutics: Voyager Therapeutics develops AAV-based gene therapies targeting severe neurological diseases including Alzheimer's, Parkinson's, and Huntington's. It is one of the most direct peers to NeuExcell given shared modality (AAV), overlapping CNS indications, and similar clinical-stage positioning.
• Prevail Therapeutics (Eli Lilly): Prevail Therapeutics, acquired by Eli Lilly, develops AAV-based gene therapies for neurodegenerative diseases including Parkinson's and frontotemporal dementia. Directly comparable to NeuExcell as an AAV gene therapy peer targeting CNS indications with similar regulatory and clinical pathways.
• uniQure: uniQure is a clinical-stage gene therapy company developing AAV-based therapies including programs for CNS disorders such as Huntington's disease (AMT-130). Comparable to NeuExcell via shared AAV modality, neurological disease focus, and similar clinical-stage status with neurodegenerative programs.
• Sangamo Therapeutics: Sangamo Therapeutics develops genomic medicines including AAV gene therapies for neurological conditions. Like NeuExcell, Sangamo is clinical-stage, modality-aligned (AAV/zinc finger platform), and pursues CNS indications with similar development timelines and capital intensity.
• Asklepios BioPharmaceutical: AskBio (acquired by Bayer) develops AAV-based gene therapies across multiple therapeutic areas including CNS disorders. Highly comparable to NeuExcell given shared AAV modality, neurological pipeline programs, and similar regulatory/commercial considerations in rare neurological diseases.

Emerging players

• BlueRock Therapeutics: BlueRock Therapeutics (Bayer) develops cell therapies and regenerative medicine approaches for neurological diseases including Parkinson's. Comparable to NeuExcell via shared regenerative medicine focus on CNS disorders, though BlueRock uses cell replacement rather than in situ conversion.
• Denali Therapeutics: Denali Therapeutics develops therapeutics for neurodegenerative diseases with BBB-crossing delivery technology for CNS targets. Overlaps with NeuExcell in Alzheimer's and other neurodegenerative indications, though Denali's modality (small molecules and biologics with delivery tech) differs from AAV gene therapy.
• Ceregene: Ceregene (acquired by Genzyme/Sanofi) developed AAV-based gene therapies for neurodegenerative diseases including Parkinson's and Alzheimer's. Comparable historical peer to NeuExcell via shared AAV modality and CNS neurodegenerative indications, offering insight into clinical and regulatory precedent for the field.

Broad incumbents

• Biogen: Biogen is a major neurological disease biopharmaceutical company with broad Alzheimer's, ALS, and multiple sclerosis franchises. Comparable as a broad incumbent in the same therapeutic indications NeuExcell targets, though Biogen operates via small molecules and biologics (e.g., Leqembi, Aduhelm) rather than AAV gene therapy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds2 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NeuExcell Therapeutics